Articles

Sanofi and Regeneron share good news from Phase III rheumatoid arthritis trial

Monoclonal antibody sarilumab, designed to act against interleukin-6 receptor, meets all three co-primary endpoints
Written byJeffrey Bouley
| 3 min read

PARIS and TARRYTOWN, N.Y.—November 22 brought news from Sanofi and Regeneron Pharmaceuticals Inc. of positive results on sarilumab—reportedly the first fully-human anti- interleukin-6 receptor (IL-6R) monoclonal antibody—in the SARIL-RA-MOBILITY Phase III clinical trial in adult patients with active rheumatoid arthritis who were inadequate responders to methotrexate therapy.

Specifically, the companies says that sarilumab treatment in combination with methotrexate improved disease signs and symptoms as well as physical function, and inhibited progression of joint damage.

Certainly Regeneron is glad to have such news to add to the momentum of its commercial success with the eye drug Eylea for wet age-related macular degeneration, but the positive results are particularly good news for Sanofi, which has seen some setbacks in its oncology research and development programs in recent months.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.